Please assess the completion status of the following clinical trial:

Trial Title: Bevacizumab and Radiation Therapy for Sarcomas

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Primary soft tissue sarcoma (STS) or an isolated local recurrence of STS. Open incisional biopsy or core biopsies should be performed within 8 weeks prior to registration~* Tumor grade of intermediate or high grade~* Tumor must be located on the upper extremity, the lower extremity, trunk, retroperitoneum, or pelvis~* Primary tumors must be \> 5.0cm in maximal diameter and local recurrence can be any size~* 18 years of age or older~* Zubrod performance status of 0-2~* Adequate organ and marrow function~Exclusion Criteria:~* Metastatic disease~* Pregnant or lactating women~* HIV positive patients~* Prior treatment with radiation, chemotherapy or biotherapy for this tumor~* History or evidence of central nervous system (CNS) disease~* Serious, non-healing wound, ulcer, or bone fracture~* Clinically significant cardiovascular disease, New York Heart Association (NYHA) Grade II or greater congestive heart failure, serious cardiac arrhythmia requiring medication, or Grade II or greater peripheral vascular disease within 1 year~* History of stroke within the past 6 months~* Major surgical procedure or significant traumatic injury within 28 days~* Current or recent (within 10 days) use of full-dose oral or parenteral anticoagulants or thrombolytic agents.~* Presence of bleeding diathesis or coagulopathy~* Proteinuria at baseline or clinically significant impairment of renal function~* History of abdominal fistula, gastrointestinal perforation, or inta-abdominal abscess within the past 6 months~* Documented history of uncontrolled seizures~* Grade 2 or greater sensory neuropathy based upon the NCI CTCAE, version 3.0~* Known history of deep vein thrombosis or pulmonary embolus~* Known hypercoagulable disorder~* History of hepatic cirrhosis or current hepatic dysfunction

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bevacizumab, Radiation, and Surgery (Type: EXPERIMENTAL): Bevacizumab 5mg/kg, external beam radiation therapy (XRT), surgery, Intraoperative radiation therapy (IORT), and postoperative external beam radiation therapy (Post-op XRT)

Based on this trial design, predict the completion outcome and termination type (if applicable).